To include your compound in the COVID-19 Resource Center, submit it here.

Ipsogen, Qiagen deal

Qiagen acquired a 61% stake in blood cancer diagnostic company Ipsogen for €12.90 per share or

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE